ASCLETIS-B (01672.HK): Submits FDA IND for ASC36_37o FDC in Obesity

On 17 November 2026, ASCLETIS-B (01672.HK) said it filed an IND with the U.S. FDA for ASC36_37o FDC, a once-weekly oral quadruple-target tablet for obesity.

NewTimeSpace News: On 17 November 2026, Ascletis Pharma Inc. (stock code: 01672) announced on a voluntary basis that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ASC36_37o FDC for the treatment of obesity. The candidate is a once-weekly oral fixed-dose combination (FDC) tablet of amylin receptor peptide agonist ASC36 and GLP-1R/GIPR/GCGR triple peptide agonist ASC37.

The Company said ASC36_37o FDC is the first once-weekly oral fixed-dose combination that combines four validated targets, namely amylin receptor, GLP-1R, GIPR and GCGR, in a single tablet. At steady state in non-human primates, the half-lives were up to 200 hours (approximately 8.3 days) for ASC36 and up to 96 hours (4 days) for ASC37, with oral bioavailability of > 10% and ≥ 9.1% respectively; combining the two peptides in one tablet extended ASC36's half-life from about 7 days as a single agent to about 8.3 days and raised its bioavailability from 6%-8% to > 10%.

In head-to-head diet-induced obese rat studies, the combination achieved approximately 69% greater body weight reduction than ASC37 monotherapy and approximately 192% greater than ASC36 monotherapy. Ascletis recently initiated a U.S. Phase I study of ASC36o, a once-weekly oral amylin receptor peptide agonist, with topline human pharmacokinetic data expected by the end of 2026. Both peptides were discovered in-house using the Company's AISBDD technology and the combination was developed with its proprietary POTENT oral peptide delivery platform. The announcement carries the Rule 18A.05 caution that the Company cannot guarantee it will ultimately develop, manufacture and/or commercialise the products successfully.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.